Voyager Acquisition Corp. (VACH)
| Market Cap | 328.90M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 6.63M |
| Shares Out | 31.63M |
| EPS (ttm) | 0.30 |
| PE Ratio | 35.18 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,686 |
| Open | 10.40 |
| Previous Close | 10.40 |
| Day's Range | 10.40 - 10.40 |
| 52-Week Range | 9.95 - 11.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About VACH
Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthcare related sectors. The company was incorporated in 2023 and is based in Brooklyn, New York. [Read more]
News
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempt...
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with...
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel...